ATA begins search for new CEO after Jonathan Linkous steps down

The American Telemedicine Association will see a new CEO soon with Jon Linkous stepping down. After 24 years as the CEO, Linkous will be replaced by Sabrina Smith, MD, acting as interim CEO until a permanent replacement is found.

“Jon was integral in the formation of the ATA and the telehealth industry,” said Peter Yellowlees, MD, MBBS, ATA’s current Board President. “We thank Jon for his many years of service and his significant contributions to ATA and the industry he helped create. The Board is pleased that Sabrina has agreed to serve in the role of interim-CEO to help us through this transitional period.”

Smith has over 20 years of experience in management roles for healthcare, academic and non-profit industries, and has served at the COO of ATA since January.

“With more than 10,000 members and 450 health system and industry partners, the largest international conference and trade show, and the most expansive educational telemedicine program in the world, the ATA is the international leader in telemedicine,” said Yellowlees. “Jon was instrumental in building this organization and we are indebted to him for building a strong foundation for future growth.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup